Renal Cell Carcinoma (RCC) Clinical Trials

Find Renal Cell Carcinoma (RCC) Clinical Trials Near You

Multi-Modality Detection of RCC Recurrence Post Ablation

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Previously received cryotherapy or microwave therapy of RCC

• Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy

• Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study

• Be at least 18 years of age

• Be medically stable

• If a female of child-bearing age, must have a negative pregnancy test

• Have signed Informed Consent to participate in the study

Locations
United States
Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITING
Philadelphia
Contact Information
Primary
John Eisenbrey, PhD
john.eisenbrey@jefferson.edu
215-503-5188
Time Frame
Start Date: 2022-11-03
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 210
Treatments
Experimental: Diagnostic (CEUS with MRI/CT)
Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study. Patients' electronic medical record is reviewed every 6 months throughout study.
Related Therapeutic Areas
Sponsors
Leads: john eisenbrey
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov